New trial demonstrates improvements in immunosuppressive treatment of patients with severe aplastic anemia
US hospitals seeing different kind of COVID surge this time
5 January 2022Nearly 2 million children worldwide develop asthma as a result of breathing in traffic-related pollution
5 January 2022New trial demonstrates improvements in immunosuppressive treatment of patients with severe aplastic anemia
Over the past three decades, efforts to improve the results of standard treatment for patients with severe aplastic anemia have been largely unsuccessful. The phase III RACE trial, sponsored by the European Society for Blood and Marrow Transplantation (EBMT), published on January 6, 2022 by the New England Journal of Medicine, now demonstrates that adding eltrombopag to standard immunosuppressive treatment is safe and increases response rates in patients with this rare, yet potentially fatal disease.
